Wells Fargo & Company Kamada LTD Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KMDA
# of Institutions
33Shares Held
6.48MCall Options Held
200Put Options Held
0-
Phoenix Holdings Ltd. Givatayim, L31.83MShares$10.8 Million0.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.38MShares$8.15 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny856KShares$5.04 Million0.01% of portfolio
-
Y.D. More Investments LTD Ramat Gan, L3710KShares$4.18 Million0.4% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny355KShares$2.09 Million0.0% of portfolio
About KAMADA LTD
- Ticker KMDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 44,800,500
- Market Cap $264M
- Description
- Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytop...